Conexiant and Elsevier have announced a licensing agreement designating Conexiant as a commercial licensing partner for The Lancet: Research in Context, a digital initiative intended to expand the reach of research published in Lancet journals among healthcare professionals and life sciences audiences. The program launched last week across 10 therapeutic areas.
Research in Context is a feature of primary research journals within the Lancet Group. It provides readers with an overview of the evidence available before a study, the contribution of new findings, and the implications of the accumulated evidence for clinical practice, policy, and future research.
The initiative includes dedicated digital platforms for specific therapeutic areas, supported by related email newsletters and engagement programs featuring Research in Context content. By organizing research around key disease areas, the platforms aim to help clinicians interpret relevant findings while maintaining direct access to the original Lancet articles. The approach is intended to improve the discoverability of published research, strengthen engagement with healthcare professionals, and support evidence-based clinical decision-making.
The initial rollout covers 10 therapeutic areas: non-small cell lung cancer, breast cancer, prostate cancer, gastric and gastroesophageal junction cancers, follicular lymphoma, multiple myeloma, gynecologic cancers, renal cell carcinoma, Alzheimer's disease, and inflammatory bowel disease.
The platform also provides a framework for future expansion and aims to increase the visibility of Lancet research among clinicians, researchers, authors, reviewers, and industry audiences worldwide.
The program is designed to provide a context-focused environment for life sciences engagement across therapeutic areas with significant ongoing research activity. Potential future applications include supporting calls for papers, recruiting peer reviewers, and developing other initiatives to strengthen connections within the global research community.
The agreement expands the existing relationship between Conexiant and Elsevier and builds on their previously announced collaboration in society marketing and member engagement. The organizations intend to use the initiative to explore additional approaches to contextual scientific communication, clinical innovation, audience engagement, and the licensed distribution of medical content.
Click here to read the original press release.
